Results 141 to 150 of about 1,461,609 (326)

Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities

open access: yesArthritis &Rheumatology, EarlyView.
Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS ...
Thalia G. Newman, Jason S. Knight
wiley   +1 more source

Function and mechanism of bispecific antibodies targeting SARS-CoV-2

open access: yesCell Insight
As the dynamic evolution of SARS-CoV-2 led to reduced efficacy in monoclonal neutralizing antibodies and emergence of immune escape, the role of bispecific antibodies becomes crucial in bolstering antiviral activity and suppressing immune evasion.
Zhaohui Li   +3 more
doaj  

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities

open access: yesMolecular Therapy: Oncolytics, 2019
Patients with Human epidermal growth factor receptor type 2 (Her2) overexpression are associated with aggressive tumor growth and poor clinical outcomes.
Jiayu Liu   +7 more
doaj  

Structural and functional characterization of IgG- and non-IgG-based T-cell-engaging bispecific antibodies

open access: yesFrontiers in Immunology
Bispecific T-cell-engaging antibodies are a growing class of therapeutics with numerous molecules being tested in clinical trials and, currently, seven of them have received market approval.
Nishant Mohan   +8 more
doaj   +1 more source

B cells and systemic sclerosis interstitial lung disease

open access: yesArthritis &Rheumatology, Accepted Article.
Interstitial lung disease is an important complication of systemic sclerosis (SSc‐ILD) with high mortality and morbidity. Recent clinical studies in SSc‐ILD have led to FDA‐approved therapies in SSc‐ILD. Importantly, evidence from these studies has been extrapolated to guide management of interstitial lung diseases of other systemic autoimmune ...
Nina Goldman   +2 more
wiley   +1 more source

Engineering antibodies with cancer‐associated binding sites

open access: yesBMEMat, EarlyView.
This review describes antibodies that perform direct/indirect roles in cancer treatment by binding to effective targets and discusses how antibodies kill tumors and modulate tumor microenvironment through these targets. The classification of expression systems for antibody production is summarized to guide appropriate selection based on different ...
Yinqi Tian   +4 more
wiley   +1 more source

Techno‐economic analysis of membrane‐based continuous capture chromatography platforms for large‐scale antibody production

open access: yesBiotechnology Progress, EarlyView.
Abstract Continuous manufacturing platforms and membrane chromatography are process technologies with the potential to reduce production costs and minimize process variability in monoclonal antibody production. This study presents a simulation and optimization framework to perform techno‐economic analyses of these strategies.
Juan J. Romero   +3 more
wiley   +1 more source

Optimizing clarification processes in biopharmaceutical manufacturing through quality by design: Strategies, implications, and future prospects

open access: yesBiotechnology Progress, EarlyView.
Abstract Biopharmaceutical manufacturing processes in which the product of interest is extracellularly expressed typically employ a clarification step following cell culture or fermentation. During clarification, crude cell culture fluid or fermentation broth is processed to remove insoluble solids, cells, debris, and other particulates, with the ...
Kyeong‐won Yeop   +7 more
wiley   +1 more source

Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study

open access: yesCancer Communications, EarlyView.
Abstract Background Cadonilimab is a humanized immunoglobulin G1 bispecific antibody targeting programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4). This study aimed to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) combined with cadonilimab in patients with advanced recurrent or ...
Yao Xiao   +7 more
wiley   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

open access: yesChemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy